The effect of rituximab adjuvant GDP regimen on non-Hodgkin lymphoma and its influence on TK-1, FASL and PDGF-BB

JI Junqin, GUO Zhiqiang, XU Ning, ZHAO Yijing, YIN Liling, LIU Jinling

主办：上海医药工业研究院
　　　中国药学会
ISSN 1672-9188   CN 31-1939/R   SLYHAA
World Clinical Drug
World Clinical Drug ›› 2025, Vol. 46 ›› Issue (12) : 1263. DOI: 10.13683/j.wph.2025.12.010
Article

The effect of rituximab adjuvant GDP regimen on non-Hodgkin lymphoma and its influence on TK-1, FASL and PDGF-BB

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2025, 46(12): 1263 https://doi.org/10.13683/j.wph.2025.12.010

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉